{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:10:27Z","timestamp":1793923827653,"version":"4.8.0"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","award":["EP\/L016044\/1"],"award-info":[{"award-number":["EP\/L016044\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["U01CA232382"],"award-info":[{"award-number":["U01CA232382"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["U54CA193489"],"award-info":[{"award-number":["U54CA193489"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Adaptive therapy seeks to exploit intratumoral competition to avoid, or at least delay, the emergence of therapy resistance in cancer. Motivated by promising results in prostate cancer, there is growing interest in extending this approach to other neoplasms. As such, it is urgent to understand the characteristics of a cancer that determine whether or not it will respond well to adaptive therapy. A plausible candidate for such a selection criterion is the fitness cost of resistance. In this article, we study a general, but simple, mathematical model to investigate whether the presence of a cost is necessary for adaptive therapy to extend the time to progression beyond that of a standard-of-care continuous therapy. Tumor cells were divided into sensitive and resistant populations and we model their competition using a system of two ordinary differential equations based on the Lotka\u2013Volterra model. For tumors close to their environmental carrying capacity, a cost was not required. However, for tumors growing far from carrying capacity, a cost may be required to see meaningful gains. Notably, it is important to consider cell turnover in the tumor, and we discuss its role in modulating the impact of a resistance cost. To conclude, we present evidence for the predicted cost\u2013turnover interplay in data from 67 patients with prostate cancer undergoing intermittent androgen deprivation therapy. Our work helps to clarify under which circumstances adaptive therapy may be beneficial and suggests that turnover may play an unexpectedly important role in the decision-making process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Tumor cell turnover modulates the speed of selection against drug resistance by amplifying the effects of competition and resistance costs; as such, turnover is an important factor in resistance management via adaptive therapy.<\/jats:p>\n                    <jats:p>See related commentary by Strobl et al., p. 811<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-20-0806","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T16:05:20Z","timestamp":1605024320000},"page":"1135-1147","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":134,"title":["Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy"],"prefix":"10.1158","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4484-8823","authenticated-orcid":false,"given":"Maximilian A.R.","family":"Strobl","sequence":"first","affiliation":[{"name":"1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida."},{"name":"2Wolfson Centre for Mathematical Biology, University of Oxford, Oxford, Oxfordshire, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"West","sequence":"additional","affiliation":[{"name":"1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-0599","authenticated-orcid":false,"given":"Yannick","family":"Viossat","sequence":"additional","affiliation":[{"name":"3Ceremade, Universit\u00e9 Paris-Dauphine, Universit\u00e9 PSL, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-6161","authenticated-orcid":false,"given":"Mehdi","family":"Damaghi","sequence":"additional","affiliation":[{"name":"4Department of Cancer Physiology, H. Lee Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0143-9587","authenticated-orcid":false,"given":"Mark","family":"Robertson-Tessi","sequence":"additional","affiliation":[{"name":"1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel S.","family":"Brown","sequence":"additional","affiliation":[{"name":"1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1621-1510","authenticated-orcid":false,"given":"Robert A.","family":"Gatenby","sequence":"additional","affiliation":[{"name":"1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida."},{"name":"5Cancer Biology and Evolution Program, H. Lee Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0146-9164","authenticated-orcid":false,"given":"Philip K.","family":"Maini","sequence":"additional","affiliation":[{"name":"2Wolfson Centre for Mathematical Biology, University of Oxford, Oxford, Oxfordshire, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-4383","authenticated-orcid":false,"given":"Alexander R.A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"key":"2022061706282811600_bib1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4aminopteroyl-glutamic acid (aminopterin)","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"key":"2022061706282811600_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0025-5564(92)90038-X","article-title":"Optimal control of tumor size used to maximize survival time when cells are resistant to chemotherapy","volume":"110","author":"Martin","year":"1992","journal-title":"Math Biosci"},{"key":"2022061706282811600_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jtbi.2008.12.006","article-title":"Modelling chemotherapy resistance in palliation and failed cure","volume":"257","author":"Monro","year":"2009","journal-title":"J Theor Biol"},{"key":"2022061706282811600_bib4","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/459508a","article-title":"A change of strategy in the war on cancer","volume":"459","author":"Gatenby","year":"2009","journal-title":"Nature"},{"key":"2022061706282811600_bib5","doi-asserted-by":"crossref","first-page":"90ra59","DOI":"10.1126\/scitranslmed.3002356","article-title":"Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling","volume":"3","author":"Chmielecki","year":"2011","journal-title":"Sci Transl Med"},{"key":"2022061706282811600_bib6","doi-asserted-by":"crossref","first-page":"e2001110","DOI":"10.1371\/journal.pbio.2001110","article-title":"How to use a chemotherapeutic agent when resistance to it threatens the patient","volume":"15","author":"Hansen","year":"2017","journal-title":"PLoS Biol"},{"key":"2022061706282811600_bib7","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","article-title":"Adaptive therapy","volume":"69","author":"Gatenby","year":"2009","journal-title":"Cancer Res"},{"key":"2022061706282811600_bib8","doi-asserted-by":"crossref","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","article-title":"Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer","volume":"8","author":"Enriquez-Navas","year":"2016","journal-title":"Sci Transl Med"},{"key":"2022061706282811600_bib9","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","article-title":"Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma","volume":"48","author":"Smalley","year":"2019","journal-title":"EBioMedicine"},{"key":"2022061706282811600_bib10","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/s41467-017-01968-5","article-title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","volume":"8","author":"Zhang","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706282811600_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-01516-1","article-title":"Spatial competition constrains resistance to targeted cancer therapy","volume":"8","author":"Bacevic","year":"2017","journal-title":"Nat Commun"},{"key":"2022061706282811600_bib12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","article-title":"Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies","volume":"78","author":"Gallaher","year":"2018","journal-title":"Cancer Res"},{"key":"2022061706282811600_bib13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtbi.2018.07.028","article-title":"Capitalizing on competition: an evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment","volume":"455","author":"West","year":"2018","journal-title":"J Theor Biol"},{"key":"2022061706282811600_bib14","first-page":"1","article-title":"Cancer therapy: attempt cure or manage drug resistance?","volume":"00","author":"Hansen","year":"2020","journal-title":"Evol Appl"},{"key":"2022061706282811600_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3897\/rethinkingecology.3.31992","article-title":"Cost of resistance: an unreasonably expensive concept","volume":"3","author":"Lenormand","year":"2018","journal-title":"Rethinking Ecol"},{"key":"2022061706282811600_bib16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: is it possible to reverse resistance?","volume":"8","author":"Andersson","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"2022061706282811600_bib17","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1096\/fasebj.2.7.3350243","article-title":"Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells","volume":"2","author":"Broxterman","year":"1988","journal-title":"FASEB J"},{"key":"2022061706282811600_bib18","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.molonc.2015.02.008","article-title":"Establishment and characterization of models of chemotherapy resistance in colorectal cancer: towards a predictive signature of chemoresistance","volume":"9","author":"Jensen","year":"2015","journal-title":"Mol Oncol"},{"key":"2022061706282811600_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jtbi.2016.11.009","article-title":"Optimization of an in vitro chemotherapy to avoid resistant tumours","volume":"413","author":"Carrere","year":"2017","journal-title":"J Theor Biol"},{"key":"2022061706282811600_bib20","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41559-018-0768-z","article-title":"Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer","volume":"3","author":"Kaznatcheev","year":"2019","journal-title":"Nat Ecol Evol"},{"key":"2022061706282811600_bib21","first-page":"5919","article-title":"Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance","volume":"50","author":"Kanzawa","year":"1990","journal-title":"Cancer Res"},{"key":"2022061706282811600_bib22","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"2022061706282811600_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00087","article-title":"Mathematical approach to differentiate spontaneous and induced evolution to drug resistance during cancer treatment","volume":"3","author":"Greene","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"key":"2022061706282811600_bib24","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1158\/0008-5472.CAN-18-3652","article-title":"Patient-specific tumor growth trajectories determine persistent and resistant cancer cell populations during treatment with targeted therapies","volume":"79","author":"Grassberger","year":"2019","journal-title":"Cancer Res"},{"key":"2022061706282811600_bib25","first-page":"1307","article-title":"Tumor size, sensitivity to therapy, and design of treatment schedules","volume":"61","author":"Norton","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"2022061706282811600_bib26","doi-asserted-by":"publisher","DOI":"10.1101\/2020.01.22.915355","article-title":"The logic of containing tumors","author":"Viossat","year":"2020","journal-title":"bioRxiv"},{"key":"2022061706282811600_bib27","article-title":"Cell plasticity in cancer cell populations.","volume":"635","author":"Shen","year":"2020","journal-title":"F1000Research"},{"key":"2022061706282811600_bib28","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1158\/1078-0432.CCR-19-0006","article-title":"Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: an evolution-based strategy","volume":"25","author":"West","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022061706282811600_bib29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.21989","article-title":"Final results of the Canadian Prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters","volume":"107","author":"Bruchovsky","year":"2006","journal-title":"Cancer"},{"key":"2022061706282811600_bib30","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.3814709","article-title":"lmfit\/lmfit-py 1.0.1 (Version 1.0.1)","volume-title":"Zenodo","author":"Newville","year":"2020"},{"key":"2022061706282811600_bib31","first-page":"1","article-title":"An evolutionary framework for treating pediatric sarcomas","volume":"0","author":"Reed","year":"2020","journal-title":"Cancer"},{"key":"2022061706282811600_bib32","volume-title":"Introduction to population ecology","author":"Rockwood","year":"2015"},{"key":"2022061706282811600_bib33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13014-015-0465-x","article-title":"A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation","volume":"10","author":"Prokopiou","year":"2015","journal-title":"Radiat Oncol"},{"key":"2022061706282811600_bib34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1086\/412574","article-title":"The refractory model: the logistic curve and the history of population ecology","volume":"57","author":"Kingsland","year":"1982","journal-title":"Q Rev Biol"},{"key":"2022061706282811600_bib35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF02514572","article-title":"Some strange properties of the logistic equation defined with r and K: inherent defects or artifacts?","volume":"33","author":"Kuno","year":"1991","journal-title":"Res Popul Ecol"},{"key":"2022061706282811600_bib36","first-page":"627","article-title":"The struggle for existence: how the notion of carrying capacity, K, obscures the links between demography, Darwinian evolution, and speciation","volume":"14","author":"Mallet","year":"2012","journal-title":"Evol Ecol Res"},{"key":"2022061706282811600_bib37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.tig.2007.03.005","article-title":"Can loss of apoptosis protect against cancer?","volume":"23","author":"Wodarz","year":"2007","journal-title":"Trends Genet"},{"key":"2022061706282811600_bib38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0014-2964(67)90022-9","article-title":"Cell loss as a factor in the growth rate of human tumours","volume":"3","author":"Steel","year":"1967","journal-title":"Eur J Cancer"},{"key":"2022061706282811600_bib39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0014-2964(73)90099-6","article-title":"The relationship between growth rate, labelling index and histological type of human solid tumours","volume":"9","author":"Malaise","year":"1973","journal-title":"Eur J Cancer"},{"key":"2022061706282811600_bib40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/bjc.1984.181","article-title":"Actual growth rate and tumour cell proliferation in human pulmonary neoplasms","volume":"50","author":"Kerr","year":"1984","journal-title":"Br J Cancer"},{"key":"2022061706282811600_bib41","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41559-019-0927-x","article-title":"A call for integrated metastatic management","volume":"3","author":"Cunningham","year":"2019","journal-title":"Nat Ecol Evol"},{"key":"2022061706282811600_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/jcb.21187","article-title":"Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize","volume":"101","author":"Fukumura","year":"2007","journal-title":"J Cell Biochem"},{"key":"2022061706282811600_bib43","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.23.167056","article-title":"Evolutionary based adaptive dosing algorithms: beware the cost of cumulative risk","author":"Mistry","year":"2020","journal-title":"bioRxiv"},{"key":"2022061706282811600_bib44","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.03.365163","article-title":"Spatial structure impacts adaptive therapy by shaping intra-tumoral competition","author":"Strobl","year":"2020","journal-title":"bioRxiv"},{"key":"2022061706282811600_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev.en.02.010157.001303","article-title":"Genetics of insect resistance to chemicals","volume":"2","author":"Crow","year":"1957","journal-title":"Annu Rev Entomol"},{"key":"2022061706282811600_bib46","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1086\/285938","article-title":"Surveying patterns in the cost of resistance in plants","volume":"148","author":"Bergelson","year":"1996","journal-title":"Am Nat"},{"key":"2022061706282811600_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.ento.54.110807.090518","article-title":"Fitness costs of insect resistance to Bacillus thuringiensis","volume":"54","author":"Gassmann","year":"2009","journal-title":"Annu Rev Entomol"},{"key":"2022061706282811600_bib48","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/jee\/96.4.1031","article-title":"Insect resistance to transgenic Bt crops: lessons from the laboratory and field","volume":"96","author":"Tabashnik","year":"2003","journal-title":"J Econ Entomol"},{"key":"2022061706282811600_bib49","volume-title":"Integrated pest management: innovation-development process","author":"Peshin","year":"2008"},{"key":"2022061706282811600_bib50","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1603\/EC11365","article-title":"Insecticide resistance and malaria vector control: the importance of fitness cost mechanisms in determining economically optimal control trajectories","volume":"106","author":"Brown","year":"2013","journal-title":"J Econ Entomol"},{"key":"2022061706282811600_bib51","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-19-2669","article-title":"Towards multidrug adaptive therapy","volume":"80","author":"West","year":"2020","journal-title":"Cancer Res"},{"key":"2022061706282811600_bib52","doi-asserted-by":"publisher","DOI":"10.1101\/2020.07.02.184952","article-title":"Modeling of collaterally sensitive drug cycles, and optimization of the drug effect in the spirit of adaptive therapy","author":"Yoon","year":"2020","journal-title":"bioRxiv"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/4\/1135\/2804690\/1135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/81\/4\/1135\/2804690\/1135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T14:47:52Z","timestamp":1655477272000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/4\/1135\/649183\/Turnover-Modulates-the-Need-for-a-Cost-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2,15]]},"published-print":{"date-parts":[[2021,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-20-0806","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22427410.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512662","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22427410","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512662.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2020.01.22.914366","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}